Floatz logo

Carfilzomib

Graft-Versus-Host Disease

University of Michigan Rogel Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Graft-Versus-Host Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 4BBB
Busulphan
City of Hope Medical Center
Phase 4BBB
Thiotepa
Memorial Sloan Kettering Cancer Center
Phase 4BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Carfilzomib is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
MRDDormant
BB
Indicative ·
64 / 100
View asset →
Stage III Adult Diffuse Large Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →